Dr Obinna C Ubah ((Principal Scientist and Future Leaders Fellow(UKRI)) and Dr Euan Murray (Senior Scientist) will be presenting the latest data on our first-in-class soloMER drug conjugate, ELN28.
Obinna’s talk, “First-in-class Site-directed targeted soloMER Drug Conjugate for autoimmune inflammation”, will be presented on Day 3 in the Nextgen, “Multi-specific, cell engagers and other new modalities” stream.
Both Obinna and Euan will be presenting posters entitled;
- A Rationally Designed First-in-class Bi-functional human anti-TNF-alpha and Janus Kinase Targeted soloMER Drug Conjugate (SDC) with Neutrophil Elastase Cleavable PEGylated Linker for Inflammation Site-specific Release of Payload.
- Development and functional characterisation of ELN28, a Novel soloMER Drug Conjugate (SDC) targeting TNFα and JAK enzymes in Immune Mediated Inflammatory Diseases.
Please come along and see the great work and progress the Elasmogen team have achieved towards tackling complex autoimmune diseases with rationally designed new therapies.